mental health

A team from the University of California (USA) has published an article questioning the scientific evidence supporting bans on social media for teenagers. Among other reasons, they argue that studies conducted to date on restricting social media use have focused on adults. Furthermore, as one of the authors points out in a press release, these restriction experiments "show weak, negligible, and mixed effects, with 40% of experimental studies reporting harmful effects (e.g., lower life satisfaction and increased loneliness) or no effect from social media restrictions." Some of the authors, whose article is published in Frontiers in Developmental Psychology, declare having ties to companies in the social media industry.

In 2023, 1.17 billion people suffered from a mental health disorder, compared to 599 million people in 1990, according to a global study published in The Lancet. Women experienced higher rates of anxiety and depression, while neurodevelopmental and behavioral disorders—such as ADHD or autism—are more common in men. The highest incidence was observed among those aged 15 to 19, which, according to the authors, underscores the need for early prevention and targeted support for this age group.

The eyes are connected to the brain via the retina, which makes it a potential pathway for brain stimulation. A study published in Cell Reports Physical Science has used contact lenses equipped with a system for transcorneal electrical stimulation to treat depression in animal models of the disorder. Mice fitted with the device showed behavioural improvements, including increased sociability, as well as physiological changes, such as the restoration of altered neural connections. The results were comparable to those obtained with fluoxetine —known commercially as Prozac— administered for three weeks in one of the mouse groups.

The hallucinogen psilocybin, found in certain mushrooms, is being investigated as a treatment for conditions such as depression. A study published in Nature Communications shows that a single 25 mg dose of the compound can produce brain changes lasting up to a month after administration. These were measured using neuroimaging techniques in 28 healthy adults who had never taken psychedelics. In terms of psychological effects, participants showed increased cognitive flexibility, psychological insight, and well-being after one month.

Individualised dosing of a synthetic inhalable formulation of mebufotenine, a psychedelic substance, led to improvements in depressive symptoms compared with placebo and was well tolerated. These are the results of a phase 2 clinical trial published in the journal JAMA Psychiatry, which includes Spanish participation. According to the authors, this supports its potential as a novel, fast-acting treatment for treatment-resistant depression.

The study of psychedelic drugs in pharmacological treatments had its eureka moment with chemist Albert Hofmann's famous bike ride under the influence of LSD in 1938 and then developed over decades, but with Richard Nixon it was shelved. In recent years, it has resurfaced in hospitals and laboratories around the world. Last week, the Congress of Deputies hosted a conference on these substances. We explain what they are, what they are used for, the current state of research, and their risks, with the help of expert sources.

Dimethyltryptamine (DMT) is responsible for the psychedelic effects of ayahuasca. According to the results of a phase IIa clinical trial published in Nature Medicine, this molecule improved depressive symptoms in adults with depression after one dose. The trial included 34 people, 17 of whom received intravenous DMT. This second group showed greater improvements in depressive symptoms than the control group. After two weeks, in the second part of the trial, DMT was administered to all participants and the antidepressant effects lasted for three months. Adverse effects were mainly pain at the injection site, nausea and transient anxiety.

The American Psychiatric Association has unveiled the new features of the forthcoming Diagnostic and Statistical Manual of Mental Disorders (DSM) in five articles published in The American Journal of Psychiatry. Among the highlights are the proposed change of name — it will become the Diagnostic and Scientific Manual — and the intention for it to be more dynamic, incorporating biomarkers for diagnosis and integrating the socioeconomic, cultural and environmental determinants of health. According to the authors, the aim is to enable a more personalised and inclusive clinical practice, aligned with scientific rigour. The most recent update was published in 2022 with the DSM-5-TR, and specialists are currently unaware of the date of the next edition, as they reported during a briefing with journalists.

The collision between two high-speed trains in Adamuz (Córdoba) on Sunday afternoon has left at least 39 people dead and more than a hundred injured. The emotional impact of the accident affects the families of the victims, as well as the crash survivors and other train users.

The journal Science has published a review of the emerging use of artificial intelligence (AI) in mental health treatment, with examples such as conversational bots for reducing depressive symptoms. The authors defend the usefulness of this technology in the different stages of psychological care, provided that the human factor, both on the part of the clinician and the patient, is the leading factor in the approach. In this regard, they emphasise that AI cannot replace clinical judgement. The distinctive characteristics of psychological care, such as the disclosure of personal information by vulnerable individuals, also necessitate regulatory frameworks that ensure ‘the ethical and effective implementation of AI technologies’.